GB202104635D0 - Methods and compositions for identifying and treating GCN2-dependent cancers - Google Patents

Methods and compositions for identifying and treating GCN2-dependent cancers

Info

Publication number: GB202104635D0
Authority: GB; United Kingdom
Prior art keywords: gcn2; identifying; compositions; treating; methods
Prior art date: 2021-03-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB2104635.4A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ip2ipo Innovations Ltd

Original Assignee

Imperial College Innovations Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-03-31

Filing date

2021-03-31

Publication date

2021-05-12

2021-03-31 Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd

2021-03-31 Priority to GBGB2104635.4A priority Critical patent/GB202104635D0/en

2021-05-12 Publication of GB202104635D0 publication Critical patent/GB202104635D0/en

2022-03-31 Priority to PCT/GB2022/050825 priority patent/WO2022208107A1/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pathology (AREA)
Immunology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

GBGB2104635.4A 2021-03-31 2021-03-31 Methods and compositions for identifying and treating GCN2-dependent cancers Ceased GB202104635D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB2104635.4A GB202104635D0 (en)	2021-03-31	2021-03-31	Methods and compositions for identifying and treating GCN2-dependent cancers
PCT/GB2022/050825 WO2022208107A1 (en)	2021-03-31	2022-03-31	Methods and compositions for identifying and treating gcn2-dependent cancers

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB2104635.4A GB202104635D0 (en)	2021-03-31	2021-03-31	Methods and compositions for identifying and treating GCN2-dependent cancers

Publications (1)

Publication Number	Publication Date
GB202104635D0 true GB202104635D0 (en)	2021-05-12

Family

ID=75783639

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB2104635.4A Ceased GB202104635D0 (en)	2021-03-31	2021-03-31	Methods and compositions for identifying and treating GCN2-dependent cancers

Country Status (2)

Country	Link
GB (1)	GB202104635D0 (en)
WO (1)	WO2022208107A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018030466A1 (en)	2016-08-10	2018-02-15	武田薬品工業株式会社	Heterocyclic compound
US20190233411A1 (en)	2018-01-29	2019-08-01	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof
US20190233425A1 (en)	2018-01-29	2019-08-01	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX390772B (en) *	2016-01-08	2025-03-21	Celgene Corp	METHODS FOR TREATING CANCER AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES.
US11788086B2 (en) *	2016-08-03	2023-10-17	Cbmed Gmbh Center For Biomarker Research In Medicine	Antitumor compounds and tumor diagnosis
GB202008749D0 (en)	2020-06-09	2020-07-22	Ip2Ipo Innovations Ltd	Novel compounds
CN112522401B (en) *	2020-11-16	2021-09-24	北京大学人民医院	Application of TOX3 gene overexpression as liver cancer prognosis marker

2021
- 2021-03-31 GB GBGB2104635.4A patent/GB202104635D0/en not_active Ceased
2022
- 2022-03-31 WO PCT/GB2022/050825 patent/WO2022208107A1/en not_active Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018030466A1 (en)	2016-08-10	2018-02-15	武田薬品工業株式会社	Heterocyclic compound
US20190233411A1 (en)	2018-01-29	2019-08-01	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof
US20190233425A1 (en)	2018-01-29	2019-08-01	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
BRAZEAUROSSE, ACS MED CHEM LETT., vol. 5, no. 4, 2014, pages 282 - 283
CIARDIELLO ET AL., ANNALS OF ONCOLOGY, vol. 31, no. 10, 2020, pages 1336 - 1349
DONG ET AL., MOL CELL, vol. 6, 2000, pages 269 - 279
DONG ET AL., MOLECULAR CELL, vol. 6, 2000, pages 269 - 279
DURINCK ET AL.: "BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis", BIOINFORMATICS, vol. 21, 2005, pages 3439 - 3440
FRIEDMAN ET AL., J STAT SOFTW, vol. 33, 2010, pages 1 - 22
FUJIMOTO, J. ET AL., ACS MED. CHEM. LETT., vol. 10, no. 1, 2019, pages 1498 - 1503
GARLAND, CURRENT BIOLOGY, vol. 24, 2014, pages R60 - 61
GU ET AL., BIOINFORMATICS, vol. 32, 2016, pages 2847 - 2849
HANAHANWEINBERG, CELL, vol. 144, 2011, pages 646 - 674
HANZELMANN ET AL., BMC BIOINFORMATICS, vol. 14, no. 7, 2013
HARDING ET AL., MOL CELL, vol. 11, 2003, pages 619 - 633
HARDING ET AL., MOLECULAR CELL, vol. 11, 2003, pages 619 - 633
HUYNH ET AL., BIOMOLECULES, vol. 9, no. 11, 2019, pages 743
JAIN ET AL., SCIENCE, vol. 336, 2012, pages 1040 - 1044
KATO ET AL., MOL. PHARM., vol. 98, no. 6, 2020, pages 669 - 676
LISTANMORE, COLD SPRING HARBOR PROTOCOLS, 2019
LOAIZA ET AL., BIOMATERIALS, vol. 183, 2018, pages 102 - 113
LOVE ET AL., GENOME BIOL, vol. 15, 2014, pages 550
LU ET AL., J. BIOMED. SCI., vol. 27, no. 1, 2020, Retrieved from the Internet <URL:http://doi.org/10.1186/s12929-019-0592>
M. E. RITCHIE ET AL.: "limma powers differential expression analyses for RNA-sequencing and microarray studies", NUCLEIC ACIDS RES, vol. 43, 2015, pages e47
MOREAU ET AL., BLOOD, vol. 120, 2012, pages 947 - 959
NAKAMURA ET AL., PNAS, vol. 115, no. 33, 2018, pages E7776 - E7785
NATURE GENETICS, vol. 49, no. 12, pages 1779 - 1784
OBENG ET AL., BLOOD, vol. 107, 2006, pages 4907 - 4916
OU ET AL., J CLIN PHARMACOL, vol. 57, 2017, pages 663 - 677
PAPADOPOULOS ET AL., J CLIN ONCOL, vol. 33, 2015, pages 732 - 739
PARZYCH ET AL., ONCOGENE, vol. 38, 2019, pages 3216 - 3231
PETROVA ET AL., ONCOGENESIS, vol. 7, 2018, pages 10
POUYSSEGUR ET AL., NATURE, vol. 441, 2006, pages 437 - 443
RIO ET AL.: "RNA: A Laboratory Manual", 2011, COLD SPRING HARBOR LABORATORY PRESS
S. DURINCKP. T. SPELLMANE. BIRNEYW. HUBER: "Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt", NAT PROTOC, vol. 4, 2009, pages 1184 - 1191
SAAVEDRA-GARCIA ET AL., AMERICAN JOURNAL OF PHYSIOLOGY: CELL PHYSIOLOGY, vol. 318, 2020, pages C451 - C462
SHAUGHNESSY, JR. ET AL., BLOOD, vol. 118, 2011, pages 3512 - 3524
SONESON ET AL., FLOOORES, vol. 4, 2015, pages 1521

Also Published As

Publication number	Publication date
WO2022208107A1 (en)	2022-10-06

Publication	Publication Date	Title
ZA202006627B (en)	2022-03-30	Methods and compositions for treating cancer
IL286350A (en)	2021-10-31	Compositions and methods for treating cancer
IL288914A (en)	2022-02-01	Compositions and methods for treating cancer
ZA202104870B (en)	2023-01-25	Methods and compositions for treating cancer
EP4100028A4 (en)	2023-07-26	Compositions and methods for treating mesothelin positive cancers
IL309296A (en)	2024-02-01	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
HUE067417T2 (en)	2024-10-28	Compositions and methods for treating egfr positive cancers
SG11202109336UA (en)	2021-09-29	Methods and compositions for treating cancer
SG11202012435UA (en)	2021-01-28	Compositions and methods for treating cancer
IL287982A (en)	2022-01-01	Compositions and methods for treating cancer
IL285886A (en)	2021-10-31	Compositions and methods for treating laminopathies
IL286153A (en)	2021-10-31	Methods and compositions for treating cancer
IL305806A (en)	2023-11-01	Compositions and methods for treating polycythemia
IL315800A (en)	2024-11-01	Compositions and methods for treating cancer
IL309120A (en)	2024-02-01	Methods and compositions for treating cancer
EP3959199A4 (en)	2023-06-28	Compositions and methods for treating ras-mutant cancers
IL304400A (en)	2023-09-01	Compositions and methods for preventing tumors and cancer
IL309662A (en)	2024-02-01	Compositions and methods for treating cancer
IL282948B1 (en)	2026-01-01	Compositions and methods for treating cancer
EP4031253A4 (en)	2023-11-01	Methods and compositions for treating myc-driven cancers
IL312846A (en)	2024-07-01	Methods and compositions for treating cancer
IL309071A (en)	2024-02-01	Methods and compositions for treating cancer
GB202104635D0 (en)	2021-05-12	Methods and compositions for identifying and treating GCN2-dependent cancers
IL308530A (en)	2024-01-01	Compositions and methods for treating lung cancer
IL314114A (en)	2024-09-01	Compositions and methods for treating mesothelin positive cancers

Legal Events

Date	Code	Title	Description
2022-12-28	AT	Applications terminated before publication under section 16(1)